Skip to main content
大唐药业 logo

大唐药业 — Investor Relations & Filings

Ticker · 920433 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2025-10-28 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920433

About 大唐药业

http://www.nmdt.com.cn/

Inner Mongolia Datang Pharmaceutical specializes in the research, development, and production of traditional Chinese and Mongolian medicines. The company focuses on modernizing ethnic medicinal formulas through advanced biotechnology and standardized manufacturing processes. Its product portfolio covers therapeutic areas including respiratory health, cardiovascular conditions, and gastrointestinal disorders. Notable offerings include Xuanfei Zhike granules and specialized Mongolian medicinal preparations. The organization integrates traditional knowledge with contemporary clinical research to develop proprietary formulations. By maintaining rigorous quality management systems and investing in automated production lines, the company aims to enhance the efficacy and accessibility of ethnic medicines for a broad patient base.

Recent filings

Filing Released Lang Actions
第四届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the sixth meeting of the fourth board of directors of Inner Mongolia Datang Pharmaceutical Co., Ltd. It includes details about the meeting's time, place, attendance, and the voting results on the agenda items. The key agenda item was the approval of the company's 2025 third quarter report, which is referenced as being disclosed separately on the official stock exchange platform. The document does not contain the actual financial data or the full report itself but rather announces the board's approval of the report. Given the document length (884 characters) and content, it fits the category of a regulatory announcement about board decisions rather than the report itself. Therefore, it is best classified as a Board/Management Information (MANG) filing, which covers announcements of changes or decisions by the board of directors.
2025-10-28 Chinese
关于对北京证券交易所2025年半年报问询函的回复
Interim / Quarterly Report Classification · 100% confidence The document is a detailed response from a company to an inquiry letter from the Beijing Stock Exchange regarding the company's 2025 semi-annual report (half-year report). It contains extensive financial data, including revenue, profit, product sales, regional sales analysis, accounts receivable, inventory, and sales expenses for the first half of 2025. The document addresses specific questions about financial performance, risks, and accounting provisions, indicating it is a substantive financial report for a period shorter than a full fiscal year. The presence of detailed financial statements and analysis confirms it is an Interim / Quarterly Report rather than a brief announcement or a certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2025
2025-10-19 Chinese
股东拟减持股份的预披露公告
Major Shareholding Notification Classification · 100% confidence The document is a pre-disclosure announcement regarding a shareholder's plan to reduce their shareholding in the company. It details the shareholder's identity, the number and percentage of shares to be reduced, the method and timing of the reduction, compliance with relevant laws and regulations, and risk disclosures. There are no financial statements, audit opinions, or management discussions of financial results. The document is a regulatory announcement about a planned shareholding reduction, which fits the category of Major Shareholding Notification (MRQ). The document length is short (2160 characters), and it is not an announcement of a report publication but a substantive disclosure about shareholding changes.
2025-10-09 Chinese
内蒙古大唐药业股份有限公司章程
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of Inner Mongolia Grand Pharmaceutical Co., Ltd. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, capital changes, and governance rules. It references relevant laws and regulatory bodies such as the China Securities Regulatory Commission and Beijing Stock Exchange listing rules. The content is a comprehensive governance document outlining internal rules and procedures rather than financial results, audit opinions, or announcements. It is not a report of financial performance or an announcement of voting results. Therefore, it fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance provisions, confirming it is the governance report itself, not a mere announcement or summary.
2025-09-14 Chinese
2025 年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2025 first extraordinary shareholders meeting of Inner Mongolia Datang Pharmaceutical Co., Ltd. It includes meeting details, attendance, voting results on various proposals, legal opinions, and personnel changes. The content focuses on the official voting results and decisions made by shareholders, including amendments to company bylaws and management systems. There is no financial data or report content, but rather the formal disclosure of voting outcomes. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is under 5,000 characters but contains full voting results, not just a notice of report publication, so it is not an RPA. Therefore, the correct classification is DVA with high confidence.
2025-09-14 Chinese
内蒙古上都律师事务所关于内蒙古大唐药业股份有限公司2025 年第一次临时股东会法律意见书
Regulatory Filings Classification · 90% confidence The document is a legal opinion letter (法律意见书) issued by an external law firm certifying the legality of procedures for an extraordinary shareholders meeting, including notice, quorum, voting process and results. It is essentially an attestation/certification rather than a substantive financial or management report, and therefore falls under a general regulatory/compliance filing.
2025-09-14 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.